DFTX

Definium Therapeutics, Inc.

Price Chart

Latest Quote

$24.48

+0.05 (+0.20%)

Current Price

Previous Close	$24.43
Open	$24.80
Day High	$25.25
Day Low	$23.80
Volume	2,233,442

Fetched: 2026-06-21T00:12:35

Stock Information

Shares Outstanding	109.07M
Total Debt	$40.77M
Cash Equivalents	$373.42M
Net Income	$-237.54M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.67B
EPS (TTM)	$-2.50
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$2.34B
Income	$-237.54M
Book/sh	$2.68
Cash/sh	$3.42
Employees	105

Financial Ratios

Quick Ratio	4.60
Current Ratio	4.69
Debt/Eq	14.62

Returns & Margins

ROA	-35.72%
ROE	-94.70%

Ownership

Insider Ownership	0.97%
Institutional Ownership	74.93%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-15.48
P/B	9.13

Analyst Data

Recommendation	strong_buy
Target Price	$39.87

Technical Indicators

SMA20	$23.64
SMA50	$22.61
SMA200	$16.28
RSI	51.77
ATR	1.5750

Shares Float	108.17M
Short Float	8.71%
Short Ratio	5.93
Volatility	2.38
Rel Volume	1.19

Performance History

Week	+1.53%
Month	+22.28%
Quarter	+31.19%
6 Months	+99.67%
YTD	+79.47%
Year	+264.83%
3 Years	+556.30%
5 Years	-58.37%
10 Years	+625.33%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$24.48	2,629,900
2026-06-17	$24.43	1,583,100
2026-06-16	$24.16	1,200,500
2026-06-15	$23.77	1,386,800
2026-06-12	$24.75	1,727,300
2026-06-11	$24.11	2,369,500
2026-06-10	$23.24	2,538,900
2026-06-09	$22.95	1,969,800
2026-06-08	$23.02	3,644,700
2026-06-05	$23.55	4,182,100
2026-06-04	$24.59	2,564,300
2026-06-03	$23.59	2,293,700
2026-06-02	$22.86	2,286,300
2026-06-01	$24.06	1,735,700
2026-05-29	$24.19	2,307,800
2026-05-28	$23.48	3,158,100
2026-05-27	$23.52	1,780,600
2026-05-26	$22.88	1,349,600
2026-05-22	$22.50	1,277,600
2026-05-21	$22.65	2,118,300
2026-05-20	$20.87	1,492,700
2026-05-19	$20.02	1,680,900

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.

📰 Latest News

A Look At Definium Therapeutics (DFTX) Valuation As Shares Show Strong Recent Momentum

Simply Wall St. • 2026-06-08T00:15:29Z

Definium Therapeutics Eyes Key DT-120 Depression Data, Advances Anxiety Program

MarketBeat • 2026-05-23T01:02:22Z

Definium Begins Second Phase 3 DT120 Trial As Valuation Gap Widens

Simply Wall St. • 2026-05-21T06:10:28Z

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Motley Fool • 2026-05-18T17:33:34Z

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Market Exclusive • 2026-05-18T14:03:51Z

Definium Therapeutics (DFTX) Deepens Losses Advancing Psychedelic Pipeline Is Its Cash Strategy Still Coherent?

Simply Wall St. • 2026-05-09T01:12:45Z

Definium Therapeutics Q1 Earnings Call Highlights

MarketBeat • 2026-05-08T01:35:41Z

Definium (DFTX) Q1 2026 Earnings Transcript

Motley Fool • 2026-05-07T22:42:59Z

A Look At Definium Therapeutics (DFTX) Valuation As DT120 ODT Nears Key Phase 2 And Phase 3 Readouts

Simply Wall St. • 2026-05-04T16:12:43Z

These 3 Psychedelic Stocks Activated After Trump's Executive Order

MarketBeat • 2026-04-27T15:15:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$5,482,000	$2,283,000	$920,000	-
Total Expenses	$166,309,000	$103,916,000	$93,866,000	$66,331,000
Other Income Expense	$-22,962,000	$-14,038,000	$-6,530,000	$8,040,000
Net Non Operating Interest Income Expense	$5,478,000	$9,275,000	$4,664,000	$1,495,000
Interest Expense Non Operating	$5,482,000	$2,283,000	$920,000	-
Operating Expense	$166,309,000	$103,916,000	$93,866,000	$66,331,000
General And Administrative Expense	$48,644,000	$38,619,000	$41,742,000	$30,162,000
Other Non Operating Income Expenses	-	-	$-51,000	$2,000
Total Other Finance Cost	-	-	$-4,664,000	$-1,495,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Net Interest Income	$5,478,000	$9,275,000	$4,664,000	$1,495,000
Interest Income	$10,960,000	$11,558,000	$5,584,000	-
Normalized Income	$-160,831,000	$-94,641,000	$-89,253,000	$-64,834,000
Net Income From Continuing And Discontinued Operation	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Total Operating Income As Reported	$-166,309,000	$-103,916,000	$-93,866,000	$-66,331,000
Net Income Common Stockholders	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Net Income	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Net Income Including Noncontrolling Interests	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Net Income Continuous Operations	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Pretax Income	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Special Income Charges	$0	$2,541,000	$0	-
Interest Income Non Operating	$10,960,000	$11,558,000	$5,584,000	-
Operating Income	$-166,309,000	$-103,916,000	$-93,866,000	$-66,331,000
Per Share
Diluted EPS	$-2.06	$-1.54	$-2.44	$-1.84
Basic EPS	$-2.06	$-1.54	$-2.44	$-1.84
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-155,349,000	$-91,831,000	$-85,171,000	$-71,189,000
Total Unusual Items	$-22,962,000	$-14,038,000	$-6,479,000	$8,038,000
Total Unusual Items Excluding Goodwill	$-22,962,000	$-14,038,000	$-6,479,000	$8,038,000
Reconciled Depreciation	$0	$527,000	$3,162,000	$3,180,000
EBITDA (Bullshit earnings)	$-178,311,000	$-105,869,000	$-91,650,000	$-63,151,000
EBIT	$-178,311,000	$-106,396,000	$-94,812,000	$-66,331,000
Diluted Average Shares	$89,327,608	$70,461,067	$39,157,420	$30,857,463
Basic Average Shares	$89,327,608	$70,461,067	$39,157,420	$30,857,463
Diluted NI Availto Com Stockholders	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Gain On Sale Of Security	$-22,962,000	$-16,579,000	$-6,479,000	$8,038,000
Research And Development	$117,665,000	$65,297,000	$52,124,000	$36,169,000
Selling General And Administration	$48,644,000	$38,619,000	$41,742,000	$30,162,000
Other Gand A	$48,644,000	$38,619,000	$41,742,000	$30,162,000
Other Special Charges	-	$-2,541,000	-	-
Tax Provision	-	-	-	$0

Fetched: 2026-06-21

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$312,409,000	$221,530,000	$57,689,000	$127,310,000
Total Assets	$440,100,000	$302,151,000	$124,541,000	$169,993,000
Total Non Current Assets	$20,780,000	$20,531,000	$20,669,000	$23,938,000
Other Non Current Assets	$862,000	$613,000	$224,000	$331,000
Goodwill And Other Intangible Assets	$19,918,000	$19,918,000	$20,445,000	$23,607,000
Current Assets	$419,320,000	$281,620,000	$103,872,000	$146,055,000
Other Current Assets	$7,727,000	$7,879,000	$4,168,000	$3,913,000
Cash Cash Equivalents And Short Term Investments	$411,593,000	$273,741,000	$99,704,000	$142,142,000
Cash And Cash Equivalents	$257,837,000	$273,741,000	$99,704,000	$142,142,000
Other Intangible Assets	-	-	$527,000	$3,689,000
Prepaid Assets	-	-	-	$3,913,000
Cash Financial	-	-	-	-
Debt
Total Debt	$40,579,000	$21,854,000	$14,129,000	$72,000
Long Term Debt And Capital Lease Obligation	$40,579,000	$21,854,000	$14,129,000	-
Long Term Debt	$40,579,000	$21,854,000	$14,129,000	-
Current Debt And Capital Lease Obligation	-	-	-	$72,000
Liabilities
Total Liabilities Net Minority Interest	$107,773,000	$60,703,000	$46,407,000	$19,076,000
Total Non Current Liabilities Net Minority Interest	$41,075,000	$21,854,000	$14,161,000	$1,184,000
Other Non Current Liabilities	$496,000	-	$32,000	$1,184,000
Current Liabilities	$66,698,000	$38,849,000	$32,246,000	$17,892,000
Other Current Liabilities	$40,905,000	$24,010,000	$16,476,000	$9,904,000
Payables And Accrued Expenses	$16,326,000	$8,434,000	$11,244,000	$4,790,000
Payables	$5,347,000	$2,010,000	$6,977,000	$3,677,000
Accounts Payable	$5,347,000	$2,010,000	$4,136,000	$2,111,000
Other Payable	-	-	$2,841,000	$1,566,000
Tradeand Other Payables Non Current	-	-	-	-
Equity
Common Stock Equity	$332,327,000	$241,448,000	$78,134,000	$150,917,000
Total Equity Gross Minority Interest	$332,327,000	$241,448,000	$78,134,000	$150,917,000
Stockholders Equity	$332,327,000	$241,448,000	$78,134,000	$150,917,000
Gains Losses Not Affecting Retained Earnings	$1,085,000	$819,000	$343,000	$627,000
Other Equity Adjustments	$1,085,000	$819,000	$343,000	$627,000
Retained Earnings	$-582,672,000	$-398,879,000	$-290,200,000	$-194,468,000
Other
Ordinary Shares Number	$98,776,265	$75,100,763	$41,101,303	$37,979,136
Share Issued	$98,776,265	$75,100,763	$41,101,303	$37,979,136
Tangible Book Value	$312,409,000	$221,530,000	$57,689,000	$127,310,000
Invested Capital	$372,906,000	$263,302,000	$92,263,000	$150,917,000
Working Capital	$352,622,000	$242,771,000	$71,626,000	$128,163,000
Total Capitalization	$372,906,000	$263,302,000	$92,263,000	$150,917,000
Additional Paid In Capital	$913,914,000	$639,508,000	$367,991,000	$344,758,000
Capital Stock	$0	$0	$0	$0
Common Stock	$0	$0	$0	$0
Pensionand Other Post Retirement Benefit Plans Current	$9,467,000	$6,405,000	$4,526,000	$3,198,000
Current Accrued Expenses	$10,979,000	$6,424,000	$4,267,000	$1,113,000
Goodwill	$19,918,000	$19,918,000	$19,918,000	$19,918,000
Other Short Term Investments	$153,756,000	$0	-	-
Capital Lease Obligations	-	-	-	$72,000
Current Capital Lease Obligation	-	-	-	$72,000

Fetched: 2026-06-21

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-131,560,000	$-79,129,000	$-64,365,000	$-50,139,000
Operating Activities
Operating Cash Flow	$-131,560,000	$-79,129,000	$-64,365,000	$-50,139,000
Cash Flow From Continuing Operating Activities	$-131,560,000	$-79,129,000	$-64,365,000	$-50,139,000
Operating Gains Losses	$22,831,000	$16,447,000	$6,273,000	$-6,491,000
Investing Activities
Investing Cash Flow	$-151,606,000	$0	-	$0
Cash Flow From Continuing Investing Activities	$-151,606,000	$0	-	$0
Financing Activities
Issuance Of Capital Stock	$258,858,000	$250,983,000	$0	$42,297,000
Financing Cash Flow	$267,269,000	$253,196,000	$21,848,000	$59,051,000
Cash Flow From Continuing Financing Activities	$267,269,000	$253,196,000	$21,848,000	$59,051,000
Net Other Financing Charges	$-12,626,000	$-8,503,000	$114,000	$-1,907,000
Net Common Stock Issuance	$258,858,000	$250,983,000	$0	$42,297,000
Common Stock Issuance	$258,858,000	$250,983,000	$0	$42,297,000
Other
Repayment Of Debt	$-22,000,000	$0	$-844,000	$0
Issuance Of Debt	$42,000,000	$10,000,000	$22,529,000	$0
Interest Paid Supplemental Data	$5,338,000	$2,224,000	$534,000	$0
End Cash Position	$257,837,000	$273,741,000	$99,704,000	$142,142,000
Beginning Cash Position	$273,741,000	$99,704,000	$142,142,000	$133,539,000
Effect Of Exchange Rate Changes	$-7,000	$-30,000	$79,000	$-309,000
Changes In Cash	$-15,897,000	$174,067,000	$-42,517,000	$8,912,000
Proceeds From Stock Option Exercised	$1,037,000	$716,000	$49,000	$18,661,000
Net Issuance Payments Of Debt	$20,000,000	$10,000,000	$21,685,000	$0
Net Long Term Debt Issuance	$20,000,000	$10,000,000	$21,685,000	$0
Long Term Debt Payments	$-22,000,000	$0	$-844,000	$0
Long Term Debt Issuance	$42,000,000	$10,000,000	$22,529,000	$0
Net Investment Purchase And Sale	$-151,606,000	$0	-	-
Sale Of Investment	$116,750,000	$0	-	-
Purchase Of Investment	$-268,356,000	$0	-	-
Change In Working Capital	$9,437,000	$-3,344,000	$6,281,000	$-3,782,000
Change In Other Current Liabilities	$-40,000	$-32,000	$-1,152,000	$-870,000
Change In Other Current Assets	$30,000	$48,000	$51,000	$-180,000
Change In Payables And Accrued Expense	$9,295,000	$977,000	$7,343,000	$-2,472,000
Change In Accrued Expense	$5,958,000	$3,103,000	$5,318,000	$-416,000
Change In Payable	$3,337,000	$-2,126,000	$2,025,000	$-2,056,000
Change In Account Payable	$3,337,000	$-2,126,000	$2,025,000	$-2,056,000
Change In Prepaid Assets	$152,000	$-4,337,000	$39,000	$-260,000
Other Non Cash Items	$1,690,000	$-993,000	$468,000	$43,000
Stock Based Compensation	$20,096,000	$16,913,000	$15,183,000	$13,707,000
Amortization Of Securities	$-1,821,000	$0	-	-
Depreciation Amortization Depletion	$0	$527,000	$3,162,000	$3,180,000
Depreciation And Amortization	$0	$527,000	$3,162,000	$3,180,000
Amortization Cash Flow	$0	$527,000	$3,162,000	$3,180,000
Amortization Of Intangibles	$0	$527,000	$3,162,000	$3,180,000
Gain Loss On Investment Securities	$22,831,000	$15,941,000	$6,636,000	$-6,343,000
Net Foreign Currency Exchange Gain Loss	$0	$506,000	$-363,000	$-148,000
Net Income From Continuing Operations	$-183,793,000	$-108,679,000	$-95,732,000	$-56,796,000
Net Business Purchase And Sale	-	-	-	$0
Purchase Of Business	-	-	-	$0
Change In Other Working Capital	-	-	-	$-180,000

Fetched: 2026-06-21